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Abstract
Background—Vaccine regimens using different agents for priming and boosting have become
popular for enhancing T cell and Ab responses elicited by candidate HIV/AIDS vaccines. Here we
use a simian model to evaluate immunogenicity and protective efficacy of a recombinant modified
vaccinia Ankara (MVA) vaccine in the presence and absence of a recombinant DNA prime. The
simian vaccines and regimens represent prototypes for candidate HIV vaccines currently
undergoing clinical testing.
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Method—Recombinant DNA and MVA immunogens expressed simian immunodeficiency virus
(SIV)mac239 Gag, PR, RT, and Env sequences. Vaccine schedules tested inoculations of MVA at
months 0, 2, and 6 (MMM regimen) or priming with DNA at months 0 and 2 and boosting with
MVA at months 4 and 6 (DDMM regimen). Twelve weekly rectal challenges with the
heterologous SIV smE660 were initiated at 6 months following the last immunization.
Results—Both regimens elicited similar 61–64% reductions in the per challenge risk of
SIVsmE660 transmission despite raising different patterns of immune responses. The DDMM
regimen elicited higher magnitudes of CD4 T cells whereas the MMM regimen elicited higher
titers and greater avidity Env-specific IgG and more frequent and higher titer SIV-specific IgA in
rectal secretions. Both regimens elicited similar magnitudes of CD8 T cells. Magnitudes of T cell
responses, specific activities of rectal IgA Ab, and the tested specificities for neutralization and
antibody-dependent cellular cytotoxicity did not correlate with risk of infection. However, the
avidity of Env-specific IgG had a strong correlation with the per challenge risk of acquisition, but
only for the DDMM group.
Conclusions—We conclude that for the tested immunogens in rhesus macaques, the simpler
MMM regimen is as protective as the more complex DDMM regimen.
Keywords
Vaccine; Immunodeficiency virus; Simian immunodeficiency virus; DNA vaccine MVA vaccine;
avidity in protection
Introduction
In the past 20 years, heterologous prime-boost vaccination regimens have become a popular
method for enhancing the elicitation of Ab and T cell responses by recombinant DNA, viral-
vectored and protein vaccines[1, 2]. In a heterologous regimen, one agent is used to prime
the immune response, and a second, to boost the immune response. The priming and
boosting agents share immunogens but are otherwise immunologically distinct. Immune
responses elicited by the 1st agent focus and augment the immune response on the
immunogen common to both agents. When used together, agents that elicit low titer immune
responses in homologous priming and boosting regimens, achieve higher titer responses.
The technique has been particularly popular for eliciting T cell responses[3, 4], but can also
be effective at enhancing Ab responses[5] [6].
In 2002, using SHIV-89.6 immunogens, we reported that MVA immunizations in the
presence or absence of a DNA prime elicited different patterns of immune responses but
similar patterns of protection for a high dose intrarectal SHIV-89.6P challenge[7]. Here, we
use a SIVmac239 (SIV239) MVA vaccine in the presence and absence of a SIV239 DNA
prime and again find similar patterns of protection; this time for a repeated SIVsmE660
(SIVE660) rectal challenge, despite the elicitation of different patterns of immune responses
[8–10]. Our results again show the DNA prime enhancing T cell responses and the MVA-
only immunizations eliciting higher Ab responses. Interestingly, the higher Env-specific Ab
responses in the MVA-only group did not translate into better prevention of acquisition. We
discuss factors that could have caused differences in the protective activity of Ab elicited by
the DDMM and MMM regimens.
1 Materials and Methods
1.1 Vaccines
DNA vaccine plasmid Rama37 expresses SIV239 Gag, PR, RT, Env, Tat, and Rev from a
single RNA by subgenomic splicing and frameshifting. A single recombinant MVA
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designated DR1 or MVASIVgpe expressed SIV239 Gag, PR, RT and Env [11] [12]. The
MVA vaccine expressed virus like particles whereas the over-expressed Gag in the DNA
vaccine formed intracellular aggregates as well as virus like particles. The DNA vaccine
expressed the complete gp160 form of Env and the MVA vaccine encoded a gp150 form of
Env that had been truncated for 146 amino acids at the C-terminus of its gp41 subunit to
enhance expression on the plasma membrane of infected cells and stabilize the insert[13].
1.2 Study Design
Animal studies were conducted at the Yerkes National Primate Research Center and
approved by the Emory University Animal Care and Use Committee. Young adult rhesus
macaques of Indian origin, pre-screened to preclude the presence of the Mamu-A*01 and
limit the presence of the Mamu-B*08 and B*17 histocompatibility types to no more than one
per group [9], were randomized into groups of 8 each. Immunization regimens were the
same as those being used in human trials[14]. For DNA/MVA immunizations, 3 mg of the
DNA vaccine (D) was administered at weeks 0 and 8 and 1×108 plaque forming units of the
MVA (M) vaccine at weeks 16 and 24 (DDMM regimen). For MVA priming and boosting,
1×108 plaque forming units of the MVA vaccine was administered at weeks 0, 8 and 24
(MMM regimen). All vaccinations were delivered intramuscularly by hypodermic needle
and syringe. Twelve weekly intrarectal challenges were initiated 6 months after the final
MVA immunization using 5000 tissue culture infectious doses50 (1.8×107 copies of viral
RNA) of the SIVE660-Hirsch2001 stock as previously described[15]. Unvaccinated controls
included nine 2–4 year old male Indian rhesus macaques that were negative for Mamu A*01,
B*08 and B*17, which underwent simultaneous challenge with the two vaccine groups; six
2–4 year old Indian rhesus males positive for Mamu A*01 that were challenged in an
overlapping trial at the Yerkes Primate Research Center, and eight 10–13 year old Indian
rhesus with mixed A*01 and B*17 Mamu types challenged at the National Cancer Institute
under the same conditions and with the same stock. TRIM5α genotype was determined by
sequence analysis of PCR fragments [16].
1.3 Humoral immune assays
Titers of Env-specific IgG and avidity indices, or the fraction of bound IgG resisting a 1.5 M
NaSCN wash × 100, were determined using ELISAs with SIV239 Env captured from VLPs
and SIVE660 ENV captured from virions as antigens [17]. Concentrations of Env-specific;
Gag, Pol-specific and total IgA in rectal secretions [18]were determined by ELISA using
plates coated respectively with rgp130mac251 (Immunodiagnostics, Woburn, MA), SIV
lysate (Advanced Biotechnologies Inc., Columbia, MD) and goat anti-monkey IgA
(AlphaDiagnostics, San Antonio, TX) [15, 19]. Neutralization assays were conducted using
pseudovirions or infectious viruses and a luciferase reporter gene assay in TZM-bl cells or
infections virus and M7-luc cells[20]. Assays for antibody dependent cellular cytotoxicity
(ADCC) were conducted using SIVmac239 gp120 (Immune Tech Corp) to coat
CEM.NKRCCR5 cells[21].
1.4 Cellular immune assays
Cellular immune assays and breadth of responses were conducted using stimulations of
PBMCs with pools of peptides (15 mers overlapping by 11) matched to the SIV239
immunogen [17]. Responding cells were scored using intracellular cytokine staining (ICS)
[22]. Breadth of responses was tested using 13 Gag and 11 Env peptide pools. Boolean
analysis was performed to measure polyfunctionality[23].
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1.5 T cells in rectal biopsies
Approximately 15–20 colorectal pinch biopsies were digested with 200U/ml of collagenase
IV (Worthington; Lakewood, NJ) with agitation for 2hr at 37°C. Tissue pieces were further
dissociated using a syringe with 18- and then 16-gauge blunt-end needles. The resultant cell
suspension was filtered with a cell strainer and used for flow cytometric analysis.
1.6 Statistics
Comparisons of immune responses between groups were done using the Wilcoxon test
(comparisons between 2 groups) and Kruksal-Wallis test (comparisons between 3 groups).
Correlations between immune responses and the number of challenges to infection used the
Spearman test. Comparisons of number of challenges until infection between groups were
done using exact log-rank tests. Models of the protective effect of vaccination were fit to
data as previously described and Akaike Information Criteria (AIC) used to select the most
parsimonious model[24, 25]. All tests were two tailed with p<0.05 considered significant.
Analyses were not corrected for multiple comparisons.
2 Results
2.1 Vaccine trial and elicited T cell responses
Groups of 8 rhesus were immunized with two inoculations of the SIV239 DNA vaccine at
weeks 0 and 8 followed by two inoculations with the SIV239 MVA vaccine at weeks 16 and
24 (DDMM regimen) or three MVA inoculations at weeks 0, 8 and 24 (MMM regimen). In
the DDMM group, T cell responses were not detected until after the 1st MVA inoculation, at
which time both CD4 and CD8 T cells achieved their maximal magnitudes with medians of
1.5% of total CD4 T cells and 0.09% of total CD8 T cells (Fig. 1, A and C). For the MMM
regimen, both CD4 and CD8 T cells were near maximal magnitudes following the 1st MVA
immunization and peaked with medians of 0.19% of total CD4 T cells and 0.13% of total
CD8 T cells following the 2nd MVA immunization (Fig. 1, B and D). The MMM regimen
elicited the highest CD4 response early in the regimen (2 and 9 weeks in the trial), whereas
the DDMM regimen elicited the highest CD4 response late in the regimen (17, 25 and 37
weeks in the trial) (Fig. 1A and B). In contrast, the MMM regimen raised the highest CD8
responses both early and late in the trial (2, 9 and 37 weeks), while both regimens had
similar magnitudes of responses following the final MVA boost (week 25) (Fig. 1C and D).
The highest magnitude CD4 and CD8 responses also had the greatest breadth (Fig. 2A and
B). Following the 1st MVA boost In the DDMM regimen, when elicited CD4 cells were
much higher than elicited CD8 T cells, CD4 responses had a median breadth of 9.5 pools
and CD8 responses a median breadth of 1.5 pools. These breadths increased to medians of
12 pools for the CD4 response and 4.5 pools for the CD8 response following the 2nd MVA
boost. In contrast, for the MMM regimen, where magnitudes of responses were overall
similar, CD4 responses had median breadths of 4.5 and 3 pools respectively after the 1st and
2nd MVA immunizations; and CD8 responses, median breadths of 4 pools following both
the 2nd and 3rd MVA boosts. For both regimens, the T cell responses were balanced between
Gag and Env (Fig. 2, C and D).
Responding cells were analyzed for patterns of co-production of IFN-γ, IL-2 and TNF-α
(Fig. 3). The DNA primed-CD4 responses showed higher percentages of IFN-γ, IL-2 and
TNF-α triple producers than the MMM regimen (55% as opposed to 26%) whereas the
MMM elicited responses showed higher percentages of IFN-γ and TNF-α double producers
(27% as opposed to 16%), and IFN-γ single producing cells (20% as opposed to 6%) than
the DDMM regimen (Fig. 3A). For both regimens, the most frequent pattern of cytokine co-
production for CD8 T cells was co-production of IFN-γ and TNF-α: 43% of the DDMM-
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elicited CD8 and 63% of the MMM-elicited CD8 cells coproduced IFN-γ and TNF-α (Fig.
3C). Despite this similarity, the functionality of the CD8 cells elicited by the 2 regimens
differed in 4 out of 7 tested patterns of cytokine co-production.
2.2 Vaccine-elicited antibody responses
The MVA-only immunizations raised by far the stronger antibody responses (Fig. 1E–F). In
contrast to T cell responses that reached their highest levels in blood early (MMM) or
midway (DDMM) through immunization regimens, the titers of Env-specific IgG increased
with each boost. Following the last immunization, the MMM regimen had elicited a median
titer of 14 μg per ml; and the DDMM regimen, a median titer of 6.6 μg per ml of Ab specific
for the SIV239 Env of the immunogen (Fig. 4A). Titers of binding Ab for the E660 Env of
the challenge virus were about 2-fold lower(Fig. 4A).
The MMM immunizations also elicited much higher avidity Env-specific IgG than the
DDMM immunizations (Fig. 4B). The avidity index for the MMM immunizations increased
from a mean of 40 post the 2nd MVA boost to a mean of 55 post the 3rd MVA boost.
Interestingly, the avidity indices for the immunizing and challenge Env were similar for the
MMM-elicited Env-specific IgG (indices of ~54) whereas, for the DDMM-elicited Ab, they
were higher for the challenge Env (index of 36) than for the immunizing Env (index of 29)
(p=0.0008).
Despite the differences in titers and avidity of elicited Env-specific IgG, the DDMM and
MMM immunizations elicited overall similar titers of neutralizing Ab (Fig. 4C). Both
regimens elicited neutralizing Ab for tier 1 (easy to neutralize) viruses (Fig. 4C) whereas
neither raised detectable responses for tier 2 (harder to neutralize) viruses (data not shown)
[26]. A HIV-2 virus (7312A/V33M) developed to test for the presence of neutralizing Ab for
the CD4i site in the presence of sub-inhibitory doses of soluble CD4 scored for similar low
activities in the presence and absence of sCD4 indicating that antibodies to the CD4i site had
not been induced[27]. The SIVE660 stock grown on CEMx174 cells, which exhibits tier 2
characteristics, did not score in the TZM-bl assay but did score at low levels when assayed
on M7-luc cells (data not shown).
ADCC activity was measured for sera harvested at peak responses and pre-challenge. This
activity was significantly higher for pre-challenge sera from the MMM group (Fig. 4D).
The MMM regimen also elicited higher IgA responses in rectal secretions than the DDMM
regimen (Fig. 4E and F). Env-specific IgA was detected in 5 of 8 MMM vaccinated animals
but in only 1 of 8 DDMM vaccinated animals; Gag,Pol specific IgA scored in 7 of 8 MMM
vaccinated animals but none of the DDMM group. The IgA responses persisted within 2-
fold of their peak in memory, whereas the median levels of SIV-specific IgG had declined
by about 5-fold by week 37.
2.3 Repeat dose rectal challenge
A repeat dose rectal challenge with 5000 TCID50 of the heterologous SIVE660 was initiated
at 6 months after the last MVA immunization. To evaluate the consistency and potential
effects of Mamu type and age on the challenge, we compared the results from 3 independent
challenge studies in Indian rhesus of different ages and Mamu type conducted at two
different institutions under the same conditions with the same SIVE660 stock. The data from
these three studies showed no differences in acquisition curves (Fig. 5A). To increase the
power of the current study we have combined data from the 3 control groups for a total
group size of 23.
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Kaplan-Meier curves for the prevention of acquisition were similar for the DDMM and
MMM regimens (Fig. 5B). Whereas 22 out of 23 of the unvaccinated animals were infected
by the 6th challenge, only 3 out of 8 MMM animals and 5 out of 8 DDMM vaccinated
animals had acquired virus following the first 6 challenges. By the 12th challenge, the one
remaining unvaccinated animal was infected whereas in both vaccine groups two out of 8
animals remained uninfected. The exact log-rank test indicates a significant difference
between the control and DDMM group (p=0.01), and between the control and the MMM
group (p=0.004), but not between the DDMM and MMM groups (p>0.05).
In modeling the protective effect for both regimens, the smallest AIC values were achieved
by assuming the vaccines had a leaky effect and there was no heterogeneity between animals
in susceptibility. For this model, the estimated probability of infection per challenge was
0.31 for an unvaccinated animal and 0.12 for DDMM vaccinated animals and 0.11 for
MMM vaccinated animals corresponding to 61% (95% CI 0.15.–0.83) and 64% (95% CI
0.14–0.76) reductions of the per challenge infection risk due to DDMM or MMM
vaccination respectively.
Analyses for levels of post challenge virus and loss of rectal CD4 T cells revealed no
significant differences between the vaccine groups and the unvaccinated group (Fig. 5C and
D). For these analyses, only the 9 animals in the simultaneously challenged group were used
as unvaccinated controls because post infection data is subject to Mamu-restriction[28, 29].
2.4 Post infection immune responses
By two weeks post infection, the vaccinated and unvaccinated animals had similar
magnitudes of SIV-specific T cell responses but highly dissimilar Env-specific Ab responses
(Fig. 6). Env-specific IgG and IgA responses were 50-fold higher in the vaccinated groups
and remained higher for the next 6 months. Despite the difference in pre-challenge IgA
responses, the two vaccine regimens had similar tempos and heights for their anamnestic
IgA responses.
Although the post infection T cell response did not show differences in magnitudes, they did
show differences in functionality (Fig. 3B & D). For CD8 T cells, some of these differences
were the same as those seen post vaccination.
2.5 Correlations
In the DDMM group, the number of exposures until infection correlated directly with the
avidity of the Env-specific IgG response for the E660 Env of the challenge virus (r=0.9,
p<0.0001)(Fig. 7A)[15]. This same correlation was not seen for the higher avidity Env-
specific IgG elicited by the MMM vaccinations (Fig. 7B). Risk for infection for the DDMM
group correlated with the avidity of the response for the E660 Env of the challenge virus, but
not with the avidity for the 239 Env of the immunogen (data not shown). No correlations
were found between the number of challenges to infection and neutralizing activity (at peak
response), ADCC (either at peak response or prechallenge), the presence of rectal IgA (at
peak response), and the magnitudes and breadths of total, Gag, or Env T cell responses (post
the 1st and 2nd MVA boosts for the DDMM regimen and post the 2nd and 3rd MVA
inoculations for the MMM regimen). Data for individual animals can be seen in
supplementary Table 1. Genotyping of the study macaques for TRIM5α alleles suggested
that Trim5 had not played a role in prevention of infection (Fig. 7C) [16].
2.6 Discussion
The SIV239 DDMM and MMM vaccine regimens raised similar levels of protection against
a repeated SIVE660 rectal challenge despite different patterns of immune responses.
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Analyses for transmission risk were most consistent with a leaky vaccine effect in which the
DDMM group had a 61% lower chance and the MMM group a 64% lower chance of
infection at each challenge than the unvaccinated group.
For the DDMM regimen, the avidity of vaccine-elicited IgG for the Env of the SIVE660
challenge was a strong correlate for reduced risk of infection. Acquisition did not occur in
the two animals with avidity indices of >40. Thus, an approach to increasing protection in
the DDMM regimen would be to increase the avidity of the Env-specific IgG by an
additional MVA boost [17, 30]. Increased avidity can also be achieved by priming with a
DNA vaccine that co-expresses GM-CSF with viral proteins [15]. The association between
avidity and protection presumably reflects Ab functions, which depend on the affinity of Ab
binding. Such functions include the breadth and strength of neutralizing activity [31] as well
as Fc-mediated activities such as ADCC, the activation of complement-mediated lysis,
opsonization and phagocytosis, and antibody-dependent virus trapping [32–34].
In contrast to the DDMM regimen, the MMM regimen did not elicit Ab with protective
avidity. In the MMM group, all of the animals had avidity indices above the protective index
for the DDMM group, yet only two remained uninfected. We suggest that this reflects
differences in conformational and linear epitopes displayed by the full length gp160 Env
expressed by the DNA vaccine and the C-terminal truncated gp150 Env expressed by the
MVA[13]. C-terminal truncations of Env affect structure as well as function and can result
in Envs with greater exposure of the CD4 binding site[35] [36], increased fusion potential
and altered Env incorporation and stability in virions[37–40]. Priming with a gp160 Env in
the DDMM regimen, as opposed to priming with a gp150 Env in the MMM regimen has the
potential for biasing immune responses for different Ab specificities by virtue of the priming
immunization establishing antigenic sin[41, 42]. Indeed, a difference in the specificity of the
Ab elicited by DDMM and MMM regimens is suggested by these two regimens eliciting
overall similar titers of neutralizing Ab despite the MMM regimen eliciting 5-times higher
titers and much higher avidity Env-specific Ab. The Ab elicited by these two regimens also
had different relative avidities for the 239 Env of the immunogen and the E660 Env of the
challenge virus. If the specificity of the Ab elicited by the DDMM and MMM regimens had
been similar, increased titers of higher avidity Ab should have resulted in increased titers of
neutralizing Ab [15] and relative avidities for the two test Envs should have been the same.
Thus, we suggest that not all high avidity Ab is protective Ab and that for high avidity Ab to
be protective, it must target conserved conformational and linear epitopes for the Env on the
challenge virus. Indeed, the avidity of the DDMM-elicited Ab for the E660 Env of the
challenge virus correlated with the number of challenges to infection whereas the avidity of
this same Ab for the 239Env of the immunogen did not show the correlation. For the avidity
to be protective, it had to represent Ab that recognized the challenge virus.
Important goals for future studies are to test a full length gp160 Env in MVA for its ability
to elicit protective avidity for a heterologous challenge. Given the good ability of the MMM
regimen to elicit Ab, the potential of this regimen to elicit Ab with protective avidity
warrants further development. If such can be achieved, our recombinant MVA vaccine,
which has proven effective at eliciting Env-specific Ab in humans[14], could provide a
single modality HIV/AIDS vaccine with an Ab correlate for protection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Protective efficacy of MVA vaccine with and without a DNA prime
Different patterns of immune responses but similar protection
Potential role of form of Env in eliciting Ab with protective avidity
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Fig. 1. Temporal patterns of vaccine-elicited T cell and Ab responses
(A) and (B) IFN-γ producing CD4 ICS responses to Gag and Env; (C) and (D) IFN-γ
producing CD8 ICS responses to Gag and Env; (E) and (F) Env-specific IgG in serum; (G)
and (H) Gag,Pol plus Env-specific IgA in rectal secretions. Responses elicited by the
DDMM regimen (turquoise) are in the left column; and those elicited by MMM (fuschia), in
the right column. T cell responses were tested at 2 weeks following the 1st inoculation, and
then, at one week following each of the subsequent vaccine inoculations. Antibody
responses were tested at 2 weeks following each inoculation. The memory response was
tested at 13 weeks following the last inoculation (week 37). Data are medians with 25th and
75th quartiles indicated. Asterisks indicate responses that are significantly higher for one
regimen than the other (*, p<0.05; **, p<0.01; ***, p<0.001). For example in panels (A) and
(B), CD4 T cell responses were significantly higher in the DDMM regimen at weeks 17, 25
and 37; and at weeks 2 and 9 in the MMM regimen. The grey boxes represent the
backgrounds for detection of specific responses.
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Fig. 2. Breadth of elicited CD4 and CD8 T cells
(A) and (B) Breadth of CD4 and CD8 T cell responses to 24 tested peptide pools; (C)and
(D) Numbers of Gag and Env pools eliciting responses. CD4 T cell responses are in the left
column; and CD8, in the right column. Responses for the DDMM regimen are in turquoise,
and those for the MMM regimen, in fuchsia. The immunization regimen is indicated on the
X axis using a D or M to indicate a DNA or MVA inoculation respectively. For example
DDM indicates two DNA and one MVA inoculation. Boxplots present medians and
interquartile ranges. * is used to indicate p<0.05; **, p<0.01; and ***, p<0.001.
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Fig. 3. Polyfunctionality of elicited CD4 and CD8 T cells at peak vaccine response and 2 weeks
post infection
Intracellular cytokine staining was used to test for patterns of IFN-γ (I), IL-2 (L) and TNF-α
(T) production in peptide stimulated cells. Peak vaccine responses (left column) were
analyzed for the DDMM regimen after the 1st MVA boost; and for the MMM regimen, after
the 2nd MVA inoculation. The right column displays responses at 2 weeks post infection.
Responses for the DDMM regimen are in turquoise; for the MMM regimen, in fuchsia and
for unvaccinated controls, in white. Boxplots present medians and interquartile ranges. In
(D), for the DDMM regimen, medians and interquartile range represent data for a sample
size of 2. * is used to indicate p<0.05; **, p<0.01; and ***, p<0.001.
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Fig. 4. Vaccine-elicited antibody responses
(A) Estimated titers of binding Ab for the SIV239 and SIVE660 Envs. (B) Avidity indices
of the elicited Env specific Ab for the SIV239 and SIVE660 Envs. (C) Neutralizing titers of
the elicited sera for tier 1 viruses. E660.11 and E660.17 are molecularly cloned Envs from
the genetically complex challenge stock. SIVE660/CG7G is a molecular clone of a recent
transmission [43]. 7312A/V33M is a HIV-2 virus mutated to test for the presence of
neutralizing Ab for the CD4i site [27]. (D) ADCC activity of the elicited sera for SIV2339
gp120 coated CEM.NKRCCR5 cells. (E) and (F) Env and Gag specific IgA in rectal
secretions at different times in the trial. The DDMM group is depicted in turquoise and the
MMM group, in fuchsia. The number of Ds and Ms indicate the number of immunizations.
Wk 37 is a memory time point. The grey boxes in (C) – (F) represent the level below which
responses are not considered significant. * is used to indicate p<0.05; **, p<0.01; and ***,
p<0.001.
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Fig. 5. Analyses for prevention of acquisition of a repeated rectal challenge and post infection
levels of viral RNA, colorectal CD4 T cells, and Env specific Ab
(A) Results of 3 independent challenges using the SIVsmE660-Hirsch2000 stock under the
same conditions. YO is year old. (B) Kaplan-Meier survival curves for vaccinated and
pooled unvaccinated animals. The exact log-rank test indicates differences in the risk of
infection for each of the two vaccine groups and the pooled control group, (C) Post
challenge levels of viral RNA in animals that became infected. The day of infection is
considered to be one week before virus was first detected in blood. (D) Post challenge levels
of rectal CD4 T cells as a percent of total CD3 T cells. Data in (C) and (D) are medians with
25th and 75th percentiles indicated. Data for DDMM-vaccinated animals are in turquoise,
those for MMM vaccinated animals in fuchsia, and those for unvaccinated animals in black.
The grey box represents the level below which responses are not considered significant.
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Fig. 6. Post infection immune responses
(A) Temporal IFN-γ producing CD4 T cell responses, (B) Temporal IFN-γ producing CD8
T cell responses, (C) Temporal Env-specific IgG responses in blood and (D) Temporal Env-
specific IgA responses in rectal secretions. T cell responses are the sum of responses to Gag
and Env. Responses in DDMM-vaccinated animals are in turquoise, those in MMM
vaccinated animals, in fuchsia, and those for unvaccinated animals, in black. The plots of
responses start with a week 48 prechallenge response. Responses have been displaced by ½
week to better allow visualization of the different curves: DDMM is plotted at −0.5 weeks,
MMM at the actual week and unvaccinated at +0.5 weeks. In (D), the grey box represents
the level below which responses are not considered significant. * is used to indicate p<0.05;
**, p<0.01; and ***, p<0.001.
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Correlation between number of challenges to infection and avidity of the vaccine-elicited Ab
for the Env of the SIVE660 challenge in DDMM (A) but not MMM (B) vaccinated animals.
Avidity measurements are for Ab collected at 2 weeks after the last immunization. (C) Lack
of a correlation with prevention with TRIM5α genotype. r designates a restrictive genotype;
m, a genotype that is heterozygous for restrictive (TRIM5α TFP or TRIM5α CYPA) and
susceptible (TRIM5αQ) genotypes, and s, a genotype that is homozygous for the susceptible
genotype. The MMM group included no animals in the “s” group. DDMM animals are in
turquoise, MMM vaccinated animals, in fuchsia; and unvaccinated animals, in black.
Animals that did not become infected are plotted at 14 challenges. Data for individual
animals can be found in supplementary Table 1.
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